Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Synlogic	GlycoMimetics	Processa Pharmaceuticals	IMARA	Evofem Biosciences
Symbol	NASDAQ:SYBX	NASDAQ:GLYC	NASDAQ:PCSA	NASDAQ:IMRA	NASDAQ:EVFM
Price Information
Current Price	$3.26	$2.25	$6.21	$7.84	$1.25
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.7	1.7	1.2	1.4	1.5
Analysis Score	3.5	3.5	0.0	3.5	3.4
Community Score	2.7	2.7	5.0	2.9	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	1.7	0.8	0.8	0.8
Earnings & Valuation Score	1.3	0.6	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$13.25	$13.00	N/A	$35.00	$10.00
% Upside from Price Target	306.44% upside	477.78% upside	N/A	346.43% upside	700.00% upside
Trade Information
Market Cap	$133.17 million	$115.96 million	$96.39 million	$137.79 million	$128.55 million
Beta	2.2	2.46	-0.06	N/A	0.07
Average Volume	979,604	786,348	70,759	142,509	4,480,289
Sales & Book Value
Annual Revenue	$2.22 million	N/A	N/A	N/A	N/A
Price / Sales	59.99	N/A	N/A	N/A	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$4.86 per share	$3.56 per share	$1.46 per share	N/A	$0.33 per share
Price / Book	0.67	N/A	N/A	N/A	N/A
Profitability
Net Income	$-51,370,000.00	$-57,890,000.00	$-3,360,000.00	N/A	$-80,030,000.00
EPS	($1.70)	($1.34)	N/A	N/A	($1.31)
Trailing P/E Ratio	N/A	N/A	0.00	0.00	N/A
Forward P/E Ratio	N/A	N/A	∞	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-2,761.83%	N/A	N/A	N/A	N/A
Return on Equity (ROE)	-41.64%	-34.22%	-79.69%	N/A	-259.47%
Return on Assets (ROA)	-34.39%	-31.43%	-53.85%	N/A	-111.70%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	0.01%	N/A	N/A
Current Ratio	16.42%	14.83%	0.14%	18.78%	1.55%
Quick Ratio	16.42%	14.83%	0.14%	18.78%	1.51%
Ownership Information
Institutional Ownership Percentage	39.53%	82.15%	N/A	64.53%	44.84%
Insider Ownership Percentage	17.95%	26.80%	54.60%	N/A	9.90%
Miscellaneous
Employees	72	54	14	27	147
Shares Outstanding	40.85 million	51.54 million	15.52 million	17.58 million	102.84 million
Next Earnings Date	5/13/2021 (Confirmed)	7/30/2021 (Estimated)	5/13/2021 (Confirmed)	8/13/2021 (Estimated)	8/3/2021 (Estimated)
Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Should Value Hunters Buy Evofem Biosciences Inc. (NASDAQ:EVFM) Stock? stocksregister.com - May 12 at 10:18 AM
	Evofem Biosciences Says FDA Grants Fast Track Designation For EVO100 - Quick Facts markets.businessinsider.com - May 12 at 10:18 AM
	Evofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women finance.yahoo.com - May 12 at 10:18 AM
	Evofem Biosciences (NASDAQ:EVFM) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS americanbankingnews.com - May 9 at 6:12 PM
	Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q1 2021 Results - Earnings Call Transcript seekingalpha.com - May 8 at 6:34 AM
	Thinking about buying stock in Epizyme, AMC Entertainment, Evofem Biosciences, Nokia, or Arcutis Biotherapeutics? benzinga.com - May 7 at 12:44 PM
	Evofem BiosciencesInc. (NASDAQ:EVFM) is down -49.38% year-to-date, but analysts find room for a price rally stocksregister.com - May 7 at 12:44 PM
	Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Update finance.yahoo.com - May 6 at 4:42 PM
	After A -46.47% Fall This Year Is Evofem Biosciences Inc. (NASDAQ:EVFM) A Better Buy Than Others? marketingsentinel.com - May 6 at 11:42 AM
	Why Evofem Biosciences, Inc. (NASDAQ:EVFM) Stock Might Be A Good Investment stocksregister.com - May 4 at 8:07 PM
	Evofem Biosciences, Inc. (NASDAQ:EVFM) Expected to Post Quarterly Sales of $2.02 Million americanbankingnews.com - May 4 at 5:10 AM
	An in-depth look at the Evofem Biosciences Inc. (EVFM) stock marketingsentinel.com - May 3 at 8:43 AM
	Evofem Biosciences, Inc. (NASDAQ:EVFM) Sees Large Growth in Short Interest americanbankingnews.com - May 3 at 1:08 AM
	-$0.49 EPS Expected for Evofem Biosciences, Inc. (NASDAQ:EVFM) This Quarter americanbankingnews.com - May 2 at 4:32 AM
	Buying Evofem Biosciences, Inc. (NASDAQ:EVFM)? Here Are Some Things to Consider stocksregister.com - April 29 at 5:39 PM
	Evofem Biosciences, Inc. (NASDAQ:EVFM) Rose 1.4% From Its 52-Week Low; YTD Numbers Fall -40.66% – Here Are Some Things To Keep In Mind marketingsentinel.com - April 29 at 12:38 PM
	Evofem Biosciences (EVFM) Scheduled to Post Earnings on Thursday americanbankingnews.com - April 29 at 4:40 AM
	Market Analysts see Evofem Biosciences Inc. [EVFM] gaining to $5. Time to buy? dbtnews.com - April 28 at 8:36 PM
	Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting finance.yahoo.com - April 28 at 3:36 PM
	Evofem Biosciences, Inc. (NASDAQ:EVFM) Given Average Recommendation of "Buy" by Brokerages americanbankingnews.com - April 27 at 6:31 AM
	Evofem Biosciences, Inc. (NASDAQ:EVFM) is up 8.76% since its low, and it’s only getting started stocksregister.com - April 26 at 2:38 PM
	Evofem Biosciences to Report First Quarter 2021 Results and Provide Corporate Update on Thursday, May 6, 2021 finance.yahoo.com - April 22 at 8:14 AM
	Evofem Biosciences Inc (EVFM) investing.com - April 18 at 9:04 PM
	Small Cap Stock Evofem Biosciences, Inc. (EVFM) is a Overweight – Analysts marketingsentinel.com - April 12 at 12:04 PM
	Evofem Biosciences Announces Closing of Public Offering of Common Stock finance.yahoo.com - March 29 at 7:32 PM

Date	Company	Brokerage	Action
3/25/2021	Synlogic	SVB Leerink	Boost Price Target
3/24/2021	Synlogic	Jonestrading	Initiated Coverage
1/13/2021	Synlogic	Chardan Capital	Boost Price Target
8/10/2020	Synlogic	HC Wainwright	Reiterated Rating
5/10/2020	Synlogic	Oppenheimer	Reiterated Rating
11/13/2019	Synlogic	Piper Jaffray Companies	Reiterated Rating
8/21/2019	Synlogic	Citigroup	Downgrade
8/9/2019	Synlogic	Wedbush	Reiterated Rating
5/3/2021	GlycoMimetics	Stifel Nicolaus	Boost Price Target
12/8/2020	GlycoMimetics	Roth Capital	Boost Price Target
3/27/2020	GlycoMimetics	Cowen	Initiated Coverage
8/5/2019	GlycoMimetics	Jefferies Financial Group	Downgrade
8/5/2019	GlycoMimetics	SunTrust Banks	Downgrade
12/8/2020	Processa Pharmaceuticals	Benchmark	Initiated Coverage
10/28/2020	Processa Pharmaceuticals	Craig Hallum	Initiated Coverage
4/26/2021	IMARA	Morgan Stanley	Lower Price Target
6/8/2020	Evofem Biosciences	Piper Sandler	Initiated Coverage
5/31/2020	Evofem Biosciences	Royal Bank of Canada	Reiterated Rating
5/22/2020	Evofem Biosciences	Cantor Fitzgerald	Reiterated Rating

(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources